11 results about "Protein kinase B" patented technology

The invention provides a functional beverage and an application thereof in anti-hypoxia. The functional beverage disclosed by the invention is obtained by compounding a lonicera caerulea extracting solution, an acanthopanax extracting solution and a schisandra chinensis extracting solution according to a specific ratio. The functional beverage can prolong the survival time of an organism in a closed hypoxia environment, relieve lung edema or hyperemia symptoms caused by hypoxia, relieve lung pathological changes caused by hypoxia, effectively reduce the levels of protein kinase B alpha, vascular endothelial cell growth factors and hypoxia-inducible factor-1 alpha in lungs, and improve the immunity of the lungs. Therefore, oxidative stress injury can be inhibited, the anti-hypoxia capability of an organism is improved, and a good anti-hypoxia effect is achieved. In addition, the functional beverage also has good biological safety, easily acceptable flavor and stable state, and is suitable for industrial popularization.

The invention relates to a pharmaceutical application of a GLP-1 receptor stimulant semeglutide, in particular to a novel pharmaceutical application of the GLP-1 receptor stimulant semeglutide, namely the semeglutide regulates hippocampal mitochondrial kinetics and mitochondrial autophagy balance by activating a phosphatidylinositol 3-kinase (PI3K) / protein kinase B (Akt) signal channel, so that the GLP-1 receptor stimulant semeglutide can be used for treating the hippocampal mitochondrial autophagy. The glial cell phenotype is regulated to be converted from a proinflammatory state to an anti-inflammatory state, and the cognitive impairment is improved. The invention determines a new medicine application method for linking the semeglutide with hippocampal pathology reduction and cognitive function recovery, and has important significance on treatment of VaD.

The invention designs a biosynthetic hydroxyapatite-based protein kinase B (Akt1) electrochemical sensor which is applied to Akt1 activity analysis in a skin cell aging process. Hydroxyapatite is biologically synthesized through bacillus subtilis and is uniformly deposited on the surface of a glassy carbon electrode by utilizing a potentiometric deposition method. The surface of the material contains rich phosphate groups and hydroxyl groups, can be combined with lanthanum ions, and provides a good interface for subsequent sensor detection. In order to detect the activity of Akt1, a substrate polypeptide containing three phosphorylation sites is designed. The Akt1 is subjected to phosphorylation of a substrate polypeptide, negative charges are increased, combination of the Akt1 and lanthanum ions on the surface of the electrode is enhanced, the impedance on the surface of the electrode is increased, and the activity of the Akt1 is reflected. And the unphosphorylated substrate polypeptide cannot be effectively attached and shows a relatively small impedance value. The accuracy of the sensor is verified by adopting an Akt1 inhibitor MK-2206. Human skin fibroblasts (GNHu49) are taken as a model, and research finds that the activity of Akt1 in senescent cells is remarkably reduced, so that an experimental basis is provided for researching the activity change of Akt1 and the change of cell functions in the skin senescence process. The invention provides a new technical means for skin aging research, anti-aging drug evaluation and cosmetic technology.

The present application relates to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating esophageal cancer and a preparation method and application thereof. The present application provides a traditional Chinese medicine composition for treating esophageal cancer, which comprises the following components: zerumbet extract, kadsura extract and trillium extract; the concentration of the zerumbet extract is 61.23-102.16 μg / mL; the concentration of the kadsura extract is 13.41-45.20 μg / mL; and the concentration of the trillium extract is 6.42-15.06 μg / mL. The traditional Chinese medicine composition can inhibit the proliferation, migration and clone formation of esophageal cancer cells, induce cell cycle arrest, and down-regulate the expression of epidermal growth factor receptor, protein kinase B and mammalian target of rapamycin.

The invention discloses a medicinal and edible composition for delaying cognitive and memory function decline of old people, which comprises a fructus piperis longi extract, a radix asparagi extract and sodium hyaluronate, and is combined with highland barley, common turnip, maca, D-psicose and other active substances to prepare the medicinal and edible composition for delaying cognitive and memory function decline of old people. A series of medicinal and edible compositions for improving cognitive and memory function decline of old people are developed. The composition disclosed by the invention has a good protective effect in delaying senile cognitive and memory function decline, can be applied to senile cognitive and memory function decline accompanied by age increase, enhances the activity of telomerase, and improves neurotransmitter homeostasis and brain health. Molecular mechanism research shows that the compound can reverse senescence of neuronal cells of hippocampus by activating key targets in a phosphatidylinositol-3-kinase / protein kinase B signal channel. The composition can be used for being developed into food and health care products for improving attention, learning ability, language ability and judgment, has safety and effectiveness, and has a very good application prospect.

This invention relates to a drug for treating ischemia-reperfusion injury and its application. The drug activates the CCL2-chemokine receptor 2 signaling axis, triggering the downstream G protein αi2 subunit-mediated phosphatidylinositol 3-kinase / protein kinase B signaling pathway. This, in turn, synergistically regulates the antioxidant defense system driven by nuclear factor erythroid 2-related factor 2 and the B-cell lymphoma 2-mediated anti-apoptotic pathway, thereby treating the ischemia-reperfusion injury. The results of this study establish a novel therapeutic strategy for testicular ischemia-reperfusion injury based on engineered exosomes, and simultaneously reveal the previously undiscovered cytoprotective role of the CCL2 / CCR2 signaling axis in non-immune cells.

The invention discloses an application of aloe floss as a protein kinase B stabilizer in preparation of a medicine for resisting recurrence of heat-resistant convulsion. The pine aloes can be combined with protein kinase B in a targeted mode, the total protein effect of the pine aloes can be stabilized, generation of a protein kinase B-CTCF protein complex is promoted, accordingly ubiquitination degradation of CTCF protein is promoted, metabolism and transcriptional steady states after the febrile convulsion are remodeled, and finally the curative effect of remarkably inhibiting relapse of the febrile convulsion is achieved.

The invention discloses a method for analyzing a drug action cell pathway based on a terahertz near-field super-resolution system. The method comprises the following steps: preparing cell samples of a control group and a drug treatment group, obtaining terahertz near-field response signals, and constructing a super-resolution terahertz image and a spectrum. Characteristic spectrum band changes under different medicine treatment are extracted, and single-frequency-point images on medicine absorption peak and trough frequencies are obtained. Analyzing the obtained terahertz image and spectrum, and extracting terahertz signal characteristic parameters of a cell nucleus region, a membrane structure and mitochondria, including structural morphology, absorption intensity, amplitude and phase; and comparing the difference generated by terahertz signal characteristic parameters with a molecular biology database, verifying whether the expressions of signal pathways such as nuclear factor kappa B, protein kinase B and epoxidase-2 are consistent with a spectrogram or not, and analyzing the effect of the drug on the cellular pathway. According to the invention, label-free detection can be carried out with nano-scale spatial resolution, and the difference between key molecules and signal channels in cells under the action of different drugs is revealed.

The present invention relates to use of SC79 or an analogue thereof in the preparation of a blood-brain barrier permeability regulator. The blood-brain barrier permeability regulator comprises SC79 or an analogue thereof as an active ingredient, which down-regulates expression of tight junction proteins Claudin-5 and Occludin by activating Claudin-5 and Occludin signaling pathway downstream the protein kinase B, and thereby increases the blood-brain barrier permeability, and enhances the efficiency of transportation of a brain targeting drug delivery system, especially, an Angiopep-2-modified glycolipid nano-delivery system, into the brain. The present invention also relates to a kit comprising the blood-brain barrier permeability regulator and a brain targeting drug delivery system. According to the present invention, use of the blood-brain barrier permeability regulator in combination with a brain targeting drug delivery system can enhance the efficiency of transportation of a brain targeting drug delivery system into the brain, and thereby improve the therapeutic efficacy of the brain targeting drug delivery system.

Application of a central small molecule protein ILF3 in the preparation of antihypertensive drugs. Essential hypertension is characterized by overactive sympathetic nerves and is closely related to the abnormal excitation of presympathetic neurons in the rostral ventrolateral medulla. Interleukin enhancer-binding factor 3 (ILF3) has multiple biological functions, such as promoting RNA synthesis, transfer, and stability. Moreover, ILF3 is expressed in blood vessels, the heart, and the central nervous system and plays an important role in maintaining normal cardiovascular function. In addition, the phosphatidylinositol 3-kinase / protein kinase B signaling pathway is involved in the regulation of the activities of various tissue cells. Therefore, by studying the role of ILF3 in the regulation of carbon monoxide production in hypertension in the RVLM, the present invention provides a feasible theoretical basis and method for treating hypertension by targeting the central small molecule protein ILF3, aiming to solve the problems of poor compliance of long-term drug treatment for the existing prevention and treatment of hypertension and high drug treatment costs.

The present invention relates to a use of Axitinib and analogs thereof in the preparation of a blood-brain barrier permeability regulator. The blood-brain barrier permeability regulator can reduce blood-brain barrier permeability, and promote recovery of a blood-brain barrier function from a pathologically impaired state to a state close to a physiological barrier. Axitinib and an analog thereof reduce blood-brain barrier permeability by inhibiting the vascular endothelial cell growth factor-phosphatidylinositol kinase-protein kinase B signaling pathway and reducing the degree to which a blood-brain barrier tight junction protein Claudin-5 / Occludin is down-regulated. The blood-brain barrier permeability regulator can be used in the treatment of a disease related to causing a change in blood-brain barrier permeability.